Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $27.17

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given a consensus rating of “Buy” by the six ratings firms that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $27.17.

IMNM has been the subject of several recent research reports. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Monday, March 10th. Lifesci Capital initiated coverage on shares of Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target on the stock.

Insider Buying and Selling

In related news, CEO Clay B. Siegall acquired 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunome

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its stake in Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock valued at $359,000 after acquiring an additional 1,520 shares during the period. Sequoia Financial Advisors LLC raised its holdings in shares of Immunome by 11.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after acquiring an additional 2,000 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Immunome by 5.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after acquiring an additional 2,005 shares during the period. Intech Investment Management LLC raised its holdings in shares of Immunome by 26.5% during the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock worth $201,000 after acquiring an additional 3,974 shares during the period. Finally, Wellington Management Group LLP raised its holdings in shares of Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after acquiring an additional 4,874 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Up 3.1 %

Shares of IMNM stock opened at $9.04 on Tuesday. The company has a 50 day moving average price of $9.93 and a 200-day moving average price of $11.71. Immunome has a 52 week low of $8.39 and a 52 week high of $26.70. The firm has a market capitalization of $721.18 million, a PE ratio of -1.11 and a beta of 1.93.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.